71
Participants
Start Date
December 20, 2021
Primary Completion Date
July 15, 2024
Study Completion Date
December 31, 2026
Tafasitamab
Administration : IV at 12mg/Kg C1 to C3: D1, D8, D15, D22 C4 to C6: D1, D15 C7 to C12: D1
Lenalidomide
Oral administration: hard capsule C1 to C6: 20mg/day C7 to C12: 15mg/day
Rituximab
Administration: IV at 375mg/m2 C1 to C6: D1
Institut de Cancérologie de la Loire Lucien Neuwirth, Saint-Priest-en-Jarez
Clinique Universitaire Saint LUC, Brussels
CHU de Liège, Liège
CHRU Mont Godinne, Yvoir
CHU de Bordeaux - Hôpital Haut Lévêque, Bordeaux
Institut Bergonié - Bordeaux, Bordeaux
CH Saint Vincent de Paul, Lille
CHRU de LILLE - Claude Huriez, Lille
Chu de Limoges - Hopital Dupuytren, Limoges
CHU de Nantes - Hôtel Dieu, Nantes
Centre Antoine Lacassagne, Nice
APHP - Hôpital Saint Louis, Paris
Centre Henri Becquerel, Rouen
Centre René Huguenin - Institut Curie, Saint-Cloud
CHU Brabois, Vandœuvre-lès-Nancy
The Lymphoma Academic Research Organisation
OTHER